News

Qurgen has obtained the FDA approval for a first-in-human Phase I clinical trial IND application for an anti-cancer transcription factor protein drug, SON-DP, for the treatment of the patients with late-stage solid tumors with the focus on: Breast Cancer including triple negative breast cancer, Ovary Cancer, Pancreatic Cancer and Colorectal Cancer.

Suzhou National High-Tech Industrial Development Zone signed a project cooperation agreement with Qurgen Inc. of the United States, establishing Qurgen (Fuent) China Pharmaceutical Co., Ltd. Xu Kunlin, Member of the Standing Committee of the Jiangsu Provincial Party Committee and Secretary…